ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

adebrelimab

Also written as “SHR-1316”, “Adebrelimab” and “Adebrelimab Injection”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Small Cell Lung Carcinoma · Pancreatic Neoplasms · Neoplasms · Breast Neoplasms, led by 2 companies.

Drug pageAdebrelimab: every studyAll 205 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 16, 201851 company-led studies, 40 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine4938 open or runningphase 3since Oct 16, 2018Apr 8, 2017Dec 2026phase 2 · NCT05482568
Hansoh Pharmaceutical Groupits history only22 open or runningphase 2since Aug 13, 2026Jul 3, 2025Mar 30, 2028phase 2 · NCT07824882

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Jiangsu HengRui Medicine only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 34 earlier studies, Apr 8, 2017 to Aug 1, 2025.

  1. Dec 9, 2019Named adebrelimabINNProposed as its International Nonproprietary Name in WHO's List 122 · before, SHR-1316
  2. Sep 4, 2025Phase 3 study in Advanced Cervical CancerNCT07168200 · 720 planned · China
  3. Nov 13, 2025Phase 3 study in Advanced Biliary Tract CancerNCT07229625 · 604 planned · China
  4. Nov 14, 2025Phase 2 study in Lung NeoplasmsNCT07241767 · 200 planned · China
  5. Dec 9, 2025Phase 2 study in Locally Advanced or Metastatic Pancreatic Cancer WithNCT07296341 · 60 planned · China
  6. Jan 30, 2026Phase 3 study in Carcinoma, Transitional CellNCT07393542 · 453 planned · China
  7. Feb 25, 2026Phase 3 study in Locally Advanced Resectable Rectal CancerNCT07454720 · 165 planned · China
  8. Apr 3, 2026Phase 3 study in Locally Advanced Gastric or Gastroesophageal Junction CancerNCT07522151 · 874 planned · China
  9. Jun 25, 2026Phase 3 study in Triple Negative Breast NeoplasmsNCT07679360 · 1,000 planned · China
  10. Jul 2, 2026Phase 3 study in Carcinoma, HepatocellularNCT07691762 · 690 planned · China
  11. Jul 10, 2026Phase 2 study in Resectable Non-small Cell Lung CancerNCT07704645 · 180 planned · China
  12. Aug 28, 2026Phase 2 study in Small Cell Lung CarcinomaNCT07798947 · 120 planned · China
  13. Sep 2, 20262 phase 2 studiesNCT07806058, NCT07863167
  14. Oct 19, 20262 phase 3 studiesNCT07896005, NCT07900789
  15. Oct 29, 2026Primary completion moved from 2031-04 to 2031-09Date moved laterphase 3 · +5 months · NCT07691762

Ahead

  1. Dec 2026Primary completion: phase 2 study in Advanced Malignant TumourNCT06915142
  2. Dec 2026Primary completion: phase 2 study in Advanced Non-small Cell Lung CancerNCT05482568
  3. Dec 30, 2026Primary completion: phase 2 study in Biliary Tract NeoplasmsNCT06465563
  4. Mar 2027Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07059221

TargetBeta

CD274 →read by rule
“An immunoglobulin G4 (IgG4), humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), ”NCIt, by rule
“Programmed cell death 1 ligand 1 inhibitor”ChEMBL 37, by rule

Other programs on CD274

ProgramCompanyFurthest phaseStudies
durvalumabruleAstraZenecaphase 4102
pumitamigBioNTechphase 334
benmelstobartruleSino Biopharmaceuticalphase 333
retlirafusp alfaruleJiangsu HengRui Medicinephase 320
Anti-PD-L1 Antibody-drug Conjugate HLX43Fosun Pharmaphase 317
erfonrilimabruleAlphamab Oncologyphase 314
Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rulenanjing-leads-biolabs-co-ltdphase 310
socazolimabruleLee's Pharmaceuticalphase 39
acasunlimabruleGenmabphase 36
sotiburafusp alfarulehuabo-biopharm-co-ltdphase 35
fetrastobart vedotinPfizerphase 32
HLX37Fosun Pharmaphase 32

Studies

All 49 Jiangsu HengRui Medicine leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07900789Systemic Treatment-naïve Pancreatic Cancer · China3Not yet recruitingNov 30, 2030825
NCT07896005Carcinoma, Non-Small-Cell Lung · China3Not yet recruitingFeb 2031436
NCT07863167Carcinoma, Non-Small-Cell Lung · China2RecruitingDec 30, 2028660
NCT07806058Pancreatic Neoplasms · China2RecruitingDec 31, 2028140
NCT07798947Small Cell Lung Carcinoma · China2RecruitingDec 2028120
NCT07704645Resectable Non-small Cell Lung Cancer · China2Not yet recruitingJun 2028180
NCT07691762Carcinoma, Hepatocellular · China3Not yet recruitingSep 2031690
NCT07679360Triple Negative Breast Neoplasms · China3RecruitingDec 20301,000
NCT07522151Locally Advanced Gastric or Gastroesophageal Junction Cancer · China3RecruitingDec 2029874
NCT07454720Locally Advanced Resectable Rectal Cancer · China3RecruitingNov 2032165
NCT07393542Carcinoma, Transitional Cell · China3RecruitingJan 31, 2028453
NCT07296341Locally Advanced or Metastatic Pancreatic Cancer With · China2RecruitingOct 202760
NCT07241767Lung Neoplasms · China2RecruitingNov 2027200
NCT07229625Advanced Biliary Tract Cancer · China3RecruitingDec 2029604
NCT07168200Advanced Cervical Cancer · China3RecruitingApr 2028720
NCT07118527Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma · China3RecruitingOct 2030600
NCT07111832Triple Negative Breast Neoplasms · China3RecruitingMar 2028400
NCT07073534Neoplasms · China2RecruitingDec 2027203
NCT07059221Squamous Cell Carcinoma of Head and Neck · China2RecruitingMar 2027210
NCT07009457Widespread Small Cell Lung Cancer · China1Active, not recruitingSep 202724
NCT06915142Advanced Malignant Tumour · China2RecruitingDec 2026300
NCT06879145Muscular Invasive Bladder Cancer (MIBC) · China3RecruitingDec 2031740
NCT06592625Untreated Early-stage or Locally Advanced Breast Cancer · China2Not yet recruitingFeb 28, 202660
NCT06465563Biliary Tract Neoplasms · China2Active, not recruitingDec 30, 202693
NCT06474468Esophageal Neoplasms · China2RecruitingOct 2026148
NCT06417554Advanced Solid Tumors · China2RecruitingDec 31, 203180
NCT06350006CLDN18.2-positive Advanced Solid Tumor · China1RecruitingDec 30, 2027924
NCT06335355Non-squamous Non-small Cell Lung Cancer · China3Not yet recruitingOct 2028401
NCT06247956Esophageal Squamous Cell Carcinoma · China2Active, not recruitingDec 30, 2025153
NCT06237257Locally Advanced Cervical Cancer · China2Active, not recruitingDec 202456
NCT06222879Breast Neoplasms · China2RecruitingOct 31, 2026350
NCT06092268Advanced Solid Tumors2Not yet recruitingDec 2025270
NCT05794477Advanced Solid Tumor · China2CompletedAug 20, 202416
NCT05671822HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma · China2RecruitingDec 2027258
NCT05482568Advanced Non-small Cell Lung Cancer · China2RecruitingDec 2026324
NCT05444088Advanced Hepatocellular Carcinoma · China2RecruitingJun 30, 2026129
NCT05416775Advanced Non-small Cell Lung Cancer · China2RecruitingJun 30, 2026168
NCT05353361Breast Neoplasms · China2UNKNOWNDec 31, 2025402
NCT05198817Advanced Malignant Tumors · China1UNKNOWNJan 31, 2023240
NCT05082545Advanced Malignant Tumors · Australia1CompletedJul 17, 202319
NCT04979390Neoplasms1UNKNOWNFeb 10, 202215
NCT04691063Small Cell Lung Carcinoma · China3By invitationMay 15, 2025486
NCT04316364Carcinoma, Non-Small-Cell Lung · China3RecruitingApr 15, 2023537
NCT04041011Small Cell Lung Carcinoma · China1CompletedApr 23, 202123
NCT03995472Advanced Malignancies · Australia, China1CompletedJan 12, 202314
NCT03732508Advanced Esophageal Squamous Cell Cancer · China2UNKNOWNNov 201930
NCT03711305Small Cell Lung Carcinoma · China3UNKNOWNOct 2022462
NCT03474289Neoplasms · China1UNKNOWNJan 30, 2019134
NCT03133247Advanced Solid Tumors · Australia1CompletedApr 9, 201937

How it is read

Names in the registry

  • “SHR-1316”, 8 entries
  • “Adebrelimab”, 6 entries
  • “Adebrelimab Injection”, 4 entries
  • “adebrelimab + SHR-A2009”, 3 entries
  • “HRS-717 + HRS-4642+SHR-1316;”, 3 entries

Codes read as this program: SHR1316.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.